Date: 2016-09-29
Type of information: R&D agreement
Compound: T cell receptor (TCR) immunotherapies against four targets
Company: Bluebird bio (USA - MA) Medigene (Germany)
Therapeutic area:
Type agreement: R&D licensing
Action mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy
Disease:
Details: * On September 29, 2016, Medigene and bluebird bio announced the signing of a strategic research and development collaboration and licensing agreement encompassing T cell receptor (TCR) immunotherapies against four targets. Under the terms of the agreement, Medigene will be responsible for the generation and delivery of the TCRs using its TCR isolation and characterization platform. Following the collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR product candidates and will receive an exclusive license for the intellectual property covering the resulting TCRs.
Financial terms: Medigene will receive an upfront payment of $ 15 million as well as potential preclinical, clinical, regulatory and commercial milestone payments, which together could total over $ 1 billion in the aggregate for the four potential TCR products across several indications. Additionally, Medigene will receive R&D funding for all work performed in the collaboration and is eligible for tiered royalty payments on net sales up to a double-digit percentage.
Latest news:
